Strides Shasun receives CCI nod for acquisition of two CNS division of Ranbaxy

22 Jan 2016 Evaluate

Strides Shasun has received order on January 21, 2016 under the Competition Act, 2002 from the Competition Commission of India (CCI) approving the proposed transaction of the company for acquisition of Ranbaxy’s two CNS divisions. With this approval, all necessary regulatory approvals have been obtained.

Last year in September, the company was in process of acquiring Ranbaxy’s two divisions in Central Nervous System (CNS) segment in India from Sun Pharmaceutical Industries for Rs 165 crore. The pharma major and Sun Pharma had entered into a definitive agreement related to erstwhile Ranbaxy’s ‘Solus’ and ‘Solus Care’ divisions.

Strides Shasun (formerly known as Strides Arcolab) is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.


Strides Pharma Scien Share Price

878.65 -7.00 (-0.79%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×